Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies Authors: Jessica L Bloom, Indira Sriram Published: 2026 ABSTRACT AbstractPurpose of reviewPeople with Down syndrome experience significant immune dysregulation, conferring elevated risk of autoimmune and inflammatory conditions. Despite the growing prevalence of adults living with Down syndrome, significant gaps remain in understanding and treating immune-mediated disease in this population. This review synthesizes current knowledge of immune dysregulation in Down syndrome, with focus on rheumatic manifestations and emerging therapeutic approaches.Recent findingsTrisomy 21 drives constitutive, global immune remodeling characterized by mixed interferon hyperactivation, hypercytokinemia, and myeloid and lymphoid subset remodeling toward an autoimmunity-prone, pro-inflammatory state. Down syndrome associated arthritis is a distinct and aggressive entity warranting recognition separate from juvenile idiopathic and rheumatoid arthritis. People with Down syndrome face elevated risk of SJIA-associated lung disease and diffuse alveolar hemorrhage. Medication tolerance is a significant consideration, including intolerance to methotrexate and diminished response to TNF inhibitors. Early clinical trials of JAK inhibitors demonstrate promising results across multiple immune-mediated manifestations, including skin disease, arthritis, and Down syndrome regression disorder.SummaryImmune dysregulation in Down syndrome is pervasive and mechanistically distinct, with interferon signaling as a central therapeutic target. Clinicians should be aware of Down syndrome specific diagnostic and management considerations, and future research should prioritize rigorous placebo-controlled trials and Down syndrome informed outcome measures.Keywords: autoimmunity, Down syndrome, interferon, JAK inhibitors, trisomy 21 INTRODUCTION Down syndrome is the most common chromosomal disorder worldwide, affecting approximately 1 in 700 infants [1]. It is caused by Trisomy 21 (T21), or the presence of three copies of chromosome 21. Life expectancy has increased from a mean of 26 years in 1950 to 53 in 2010 [2]. Despite their ability to thrive, many people with Down syndrome have multiple unmet needs, particularly regarding immune dysfunction and its management [3,4]. People with Down syndrome have a distinct clinical profile. This includes decreased risk of solid tumors, atherosclerosis, hypertension, and allergies and increased risk of Alzheimer's disease, childhood leukemia, lung infections, congenital heart defects, vision and hearing pathology, and autoimmunity. Individuals with Down syndrome are more susceptible to severe respiratory infections, a leading cause of death, and have a high risk of early-onset Alzheimer's disease, which contributes to morbidity and mortality [5–9]. This review examines the unique immunological landscape of people with Down syndrome and its management. We begin by highlighting distinct features of the immune system, including increased interferon signaling, before addressing specific autoimmune manifestations. We conclude with management challenges and emerging therapeutic approaches. no caption available IMMUNE DYSREGULATION Immune profiling in Down syndrome is characterized by hypercytokinemia, increased Type I (α/β) and Type II (γ) interferon signaling, B cell depletion, T cell activation and exhaustion, and accelerated immune senescence marked by a pronounced shift from naïve to memory and effector lymphocytes [10–13,14▪,15]. These changes are summarized in Fig. 1. Overview of immune dysregulation in Down syndrome. Overview of the dysregulation noted in the innate and adaptive immune systems of people with Down syndrome, as well as resultant clinical outcomes. Innate immunity Innate immune dysregulation from T21 encompasses reduced eosinophils in childhood and defective monocyte phagocytosis and chemotaxis, alongside altered dendritic and NK cell populations. The complement system is also dysregulated and elevated neopterin and cytokines, including IL-6 and TNF, demonstrate a chronic inflammatory state [16,17▪▪,18,19▪▪]. T21 causes persistently activated IFN transcriptional signaling, with enhanced sensitivity to IFN stimulation and hyperactivation of downstream JAK/STAT signaling, attributable to an extra copy of chromosome 21, which harbors four of six IFN-receptor genes (IFNAR1, IFNAR2, IFNGR2, IL10RB) (Fig. 2) [10,20▪,21,22]. T21-driven changes in the circulating proteome are indicative of chronic autoinflammation, and IFN transcriptional scores correlate with immune remodeling and hypercytokinemia [16,21]. Downstream consequences of increased IFN signaling include neurotoxic tryptophan catabolites via the kynurenine pathway and impaired cardiac differentiation through dysregulation of Wnt signaling in mice and in-vitro cell cultures [23,24]. Notably, restoring IFN signaling rescues cardiogenesis defects both in vitro (cell lines) and in vivo (mouse model) [23]. JAK inhibition in a mouse model improved cognition and rescued changes in neuroinflammatory and Alzheimer's disease-associated gene expression [20▪]. Correcting IFNR gene copy number in a mouse model normalized antiviral responses, prevented congenital heart defects, and improved cognition, craniofacial anomalies, and developmental delays, suggesting that T21 should classify as an interferonopathy [10]. Increased interferon signaling in trisomy 21 and JAK inhibition. (a) Four of the six interferon receptors reside on chromosome 21, leading to increased interferon receptor expression in people with trisomy 21. (b) This leads to increased interferon signaling via the JAK-STAT pathway and ultimately increased gene transcription of interferon-stimulated response elements. JAK-inhibitors block the JAK-STAT pathway, therefore inhibiting interferon signaling Innate immune dysregulation from T21 contributes to increased viral infection severity and promotes the development of autoimmune disease. The former is driven in part by excessive negative feedback of the type I IFN pathway [25]. Adaptive immunity T21 is associated with reduced B and T cell counts in childhood [14▪,26]. While T cell levels normalize by adulthood, B cell lymphopenia persists, particularly in transitional, naive mature, and memory B cell subsets. Atypical CD11c+ B cells are elevated, alongside low CXCR5 and high CXCR3 expression, mirroring B cell profiles seen in diseases such as lupus and rheumatoid arthritis [25,27]. Despite broadly normal IgG and IgA levels, IgM is reduced and autoantibody production, including rheumatoid factor, is markedly elevated [17▪▪,28,29]. Low levels of class-switched memory B cells further contribute to increased infection severity [30]. These B cell alterations have downstream implications for vaccine response and longevity, discussed further below [31–33]. People with T21 also have fewer total T cells in childhood and young adulthood, a higher proportion of peripheral TCRγδ+ cells, and altered thymic maturation [26,34–37]. Naive CD4+ and CD8+ compartments are reduced, with expansion of memory and regulatory T cells, likely secondary to chronic immune activation [34–36,38–41]. CD8+ T cells produce elevated cytokines, and naive, activated, and central memory CD4+ T cells show baseline JAK-dependent STAT phosphorylation [25]. Abnormal expression of immune genes impacting adaptive immunity (such as AIRE, ZAP70, and FCRL4) is also noted [14▪]. Rachubinski et al.[17▪▪] suggest that immune remodeling in T21 toward an autoimmunity-prone, pro-inflammatory state begins early in life, as hypercytokinemia and myeloid and lymphoid subset changes were observed independent of clinical autoimmune disease or autoantibody positivity. The authors propose that this either reflects a prolonged preclinical inflammatory period preceding autoimmune disease, or that hypercytokinemia itself directly underlies many defining features of Down syndrome [17▪▪]. AUTOIMMUNE DISEASES ASSOCIATED WITH TRISOMY 21 People with Down syndrome experience increased rates of autoimmune conditions, including Type 1 diabetes, celiac disease, Graves’ disease, and autoimmune skin conditions, with at least 75% of adults affected by at least one diagnosis and 38% by at least two (Table 1) [17▪▪,25,42]. Thyroid disease affects approximately 50% of adults with Down syndrome, celiac disease 10%, and inflammatory arthritis 1% [17▪▪,43–45]. Data from the Crnic Institute's Human Trisome Project (n = 441, ages 6 months to 57 years) found that 80% of thyroid, skin, and celiac diagnoses occurred by age 20, and 82.4% of adults had anti-TPO or ANA antibodies, with 41.2% having both. Twenty-five autoantibodies targeting tissues throughout the body were over-represented relative to age- and sex-matched controls, with two-thirds positive for six or more; notable associations included anti-MuSK with co-occurring neurologic conditions and anti-TPO with ear tube history. Elevated anti-SRP68, typically seen in necrotizing myopathies, were also noted [17▪▪]. Immunodeficiency also occurs in Down syndrome but is beyond the scope of this review. Table 1Prevalence of autoimmune conditions in people with Down syndromeBody systemSpecific conditionPrevalence in DSOverall≥1 autoimmune conditiona~75%≥2 autoimmune conditions38.4%≥3 autoimmune conditions13.6%EndocrineAutoimmune thyroid disease50–53.1%Type 1 diabetes2.2%GastrointestinalCeliac diseaseb5–9.6%MusculoskeletalInflammatory arthritis~1%SkinAny autoimmune skin disease43%Atopic dermatitis27.9%Hidradenitis suppurativa20.6%Alopecia areata7.7%Psoriasis6.1%Vitiligo1.9%aOver 80% diagnosed in childhood.bOften diagnosed before age 20 years.Adapted from [17▪▪]. Prevalence of autoimmune conditions in people with Down syndrome Over 80% diagnosed in childhood. Often diagnosed before age 20 years. Adapted from [17▪▪]. Down syndrome-associated arthritis Down syndrome-associated arthritis (DAA) is an aggressive, immune-mediated arthritis affecting approximately 8.7 per 1000 children with Down syndrome [46]. Despite overlapping features with juvenile idiopathic arthritis (JIA) and rheumatoid arthritis, several distinct characteristics support its classification as a separate entity. DAA most commonly presents as polyarticular arthritis, with an average of fifteen joints affected at onset, though oligoarticular presentations with subsequent polyarticular progression are also seen. Onset typically occurs between ages 2 and 12, with equal sex distribution. DAA often follows a more aggressive and erosive course than JIA, compounded by a mean diagnostic delay of approximately two years, driven by provider unfamiliarity and the challenges of clinical assessment in individuals with developmental delay, altered pain expression, and joint hypermobility [45,47,48,49▪▪,50,51]. A multicenter study recently developed and evaluated a musculoskeletal screening tool to identify DAA during routine clinical care [49▪▪]. Systemic-onset juvenile idiopathic arthritis and associated lung disease Systemic-onset juvenile idiopathic arthritis (SJIA) involves inflammatory arthritis with systemic features such as fever, rash, and serositis, and carries risk of severe complications, including macrophage activation syndrome and lung disease. SJIA-LD is a rare but potentially fatal complication characterized by lymphocytic interstitial inflammation and accumulation of lipoproteinaceous material and lipid-laden macrophages in the alveoli. T21 is one of five known risk factors for SJIA-LD, as 10% of the largest SJIA-LD cohort had T21 compared to 0.2% of the SJIA cohort without known lung disease. SJIA-LD is driven primarily by type II IFN (IFN-γ), evidenced by IFN-driven pulmonary gene expression and elevated IL-18 and IFN-γ-driven chemokines in the lungs [52,53]. IFN hyperactivation characteristic of T21 may further potentiate lung disease development in these patients. Additional contributing factors include abnormal lung development in DS and elevated risk of IL-1 and IL-6 inhibitor intolerance in Down syndrome, an independent risk factor for SJIA-LD development [54]. Immune-mediated diffuse alveolar hemorrhage Diffuse alveolar hemorrhage (DAH), or bleeding into the alveolar spaces due to alveolar-capillary basement membrane disruption, is a life-threatening condition occurring more frequently in children with Down syndrome. A 2018 French RespiRare Network study identified a 75-fold higher prevalence of idiopathic DAH in children with Down syndrome, with earlier onset and greater morbidity and mortality [55]. Bloom et al.[56] described five children with Down syndrome and DAH, all with autoimmune disease or autoantibodies of unknown significance and responded to glucocorticoids, IVIG, and/or rituximab. A literature review identified similar patterns, with drivers including congenital cardiopulmonary abnormalities, pulmonary arterial hypertension, infection, aspiration, and immune dysregulation [56–58]. A minority had hemoptysis. A low threshold for considering DAH should be maintained in children with Down syndrome presenting with anemia or presumed recurrent pneumonia, with or without hemoptysis, given the increased prevalence and potential for immune-mediated causes. MANAGEMENT OF AUTOIMMUNITY IN PEOPLE WITH DOWN SYNDROME: UNIQUE CHALLENGES Medication tolerance Glucocorticoid side effects, including obesity, hyperglycemia, irritability, and poor sleep, are of particular concern given the increased prevalence of metabolic syndrome, behavioral and mood disorders, and obstructive sleep apnea [59,60] (Fig. 3). Methotrexate, a cornerstone of treatment for inflammatory arthritis, is frequently poorly tolerated in Down syndrome, with increased rates of mouth ulcers, gastrointestinal upset, and bone marrow suppression [61–63]. This is hypothesized to result from triplication of the reduced folate carrier gene (SLC19A1), increasing cellular methotrexate uptake across tissues, compounded by preexisting alterations in folate-dependent purine synthesis pathways [64]. People with Down syndrome may also demonstrate diminished response to TNF inhibitors. Data from the Childhood Arthritis and Rheumatology Research Alliance showed treatment failure with anti-TNF therapy in 60% of patients with Down syndrome compared to 17% in a JIA cohort without Down syndrome, likely reflecting the interferon-driven rather than TNF-driven nature of inflammation in Down syndrome associated arthritis, compounded by baseline TNF elevation reducing efficacy of standard dosing [48]. Considerations for the use of immune-modulating therapies in people with Down syndrome. The use of immunosuppressive medications in people with Down syndrome requires taking into account unique considerations. These include medication tolerance (a), medication efficacy (b), vaccine efficacy (c), polypharmacy (d), developmental accommodations (d), and more Vaccine response Management of autoimmunity in people with Down syndrome is complicated by potential suboptimal and waning vaccine responses, leaving patients vulnerable to vaccine-preventable illness despite prior vaccination [33,65,66]. Vaccinations against pneumococcal infection, COVID-19, and influenza should be kept up to date, particularly in those on immunosuppressive therapy [67]. Certain immunosuppressive agents, such as JAK inhibitors, also warrant herpes zoster vaccination. Providers should review vaccine status prior to initiating immunosuppressive therapy, with particular attention before rituximab use. Special considerations Management plans must be developed through shared decision-making with patients and their families, with the individual patient's needs in mind. Many characteristics of Down syndrome influence medication and therapy selection, such as developmental delay, care coordination, swallowing difficulties, and/or aspiration risk [68,69]. Co-occurring conditions increase polypharmacy risk, while developmental delay may limit patients’ ability to communicate side effects or tolerate blood draws. Lower thresholds for sedation during imaging or procedures, combined with cardiac and pulmonary comorbidities, present additional challenges during evaluation and management [70]. NEW FRONTIERS As understanding of immune dysregulation in Down syndrome grows, the field is moving toward more targeted and personalized interventions. JAK inhibitors (JAKi) have emerged as a promising path forward as they suppress IFN-driven JAK/STAT signaling, reduce interferon-stimulated gene transcription, and dampen cytokine responses, and are already approved for conditions such as JIA, ulcerative colitis, alopecia areata, and monogenic interferonopathies [71]. In Down syndrome mouse models, JAKi prevented lethal immune hypersensitivity and normalized gene expression, and when administered to pregnant mice, prevented congenital heart defects [21,23,72]. In humans, case reports have documented successful treatment of alopecia areata, arthritis, and SJIA-LD with JAKi in people with Down syndrome [73–76]. The Crnic Human Trisome Project conducted a single-site, open-label phase II trial of tofacitinib – a JAK1/3 inhibitor, selected given JAK1's use by all four chromosome 21-encoded IFN receptors – in people with Down syndrome aged 12–50 with moderate-to-severe alopecia areata, hidradenitis suppurativa, psoriasis, atopic dermatitis, or vitiligo. Participants received tofacitinib 5 mg twice daily for 16 weeks, with an optional 40-week extension; primary endpoints were safety and reduction in whole-blood IFN transcriptional scores. An interim analysis of the first 10 completers demonstrated normalized IFN scores, decreased TNF and IL-6, reduced pathogenic autoantibodies, and improved skin disease and quality of life. Notably, cytokine levels normalized to non-Down syndrome population levels, rather than below, and remained stimulus-responsive, suggesting limited immunosuppression risk. Though lacking a placebo arm, improvements in spatial and episodic memory, visuomotor, and verbal tasks were noted after 16 weeks. No severe or definitively drug-attributable adverse events occurred, and no participants required dose modification or discontinuation [17▪▪]. Preliminary cognitive findings from the above tofacitinib trial contributed to the development of a trial targeting Down syndrome regression disorder (DSRD), an acute or subacute regression in cognition, self-care, and speech, often with psychosis, catatonia, or obsessive-compulsive disorder, typically resulting in significant impairment and often incomplete functional recovery [77]. A neuroinflammatory etiology is supported by inflammatory CSF, MRI, and EEG findings, impaired blood-brain barrier integrity, immune profiles resembling neuroinflammatory rather than healthy controls, and elevated autoantibodies including TPO and celiac-associated antibodies, with 45% having a personal autoimmune history [78,79▪▪,80]. A prospective observational study of 212 patients with DSRD found IVIG superior to lorazepam and both superior to no treatment across all five outcomes at 24 weeks [81▪▪]. A three-patient case series showed significant neurological improvement with tofacitinib, and a phase II trial evaluating lorazepam, IVIG, and tofacitinib is currently underway [82▪]. THE ROAD AHEAD Significant efforts to advance Down syndrome research are underway, driven by organizations including the NIH INCLUDE initiative, the Global Down Syndrome Foundation, the Trisomy 21 Research Society, and international Down Syndrome Medical Interest Groups. Recent work has addressed research priorities including community engagement, global funding, and policy reform, Down syndrome informed clinical trial design and syndrome-specific outcome measures, research representation, and family participation drivers [83▪,84–86]. While many questions remain, the work discussed here offers hope for future preventive and therapeutic strategies to improve outcomes for people with DS. In the near term, questions include whether JAKi should be initiated earlier for Down syndrome associated autoimmune conditions, such as DAA, rather than later as per standard treatment tiers. More broadly, whether blocking interferon signaling may be beneficial independent of a known autoimmune diagnosis remains an open question, with a phase II double-blind randomized trial underway to assess safety, neurodevelopmental effect, and global health impact of tofacitinib in people with Down syndrome ages 6–22 years without a required co-occurring condition. Future targets may include the JAK/STAT pathway, IFNs ligands, and mediator kinases driving IFN-dependent cytokine responses [17▪▪,87▪]. The benefits of JAKi may partly reflect effects on autoreactive B cells and B cell lineage remodeling, raising the potential for B cell-mediated therapies [88]. With continued focus on immune dysregulation in Down syndrome, there is great hope that the path forward will enhance the lives of this vibrant community. Acknowledgements The authors wish to thank Drs. Angela Rachubinski, Robert Fuhlbrigge, and Joaquin Espinosa for their thoughtful review of the manuscript. The authors used generative artificial intelligence tools to assist with shortening and editing portions of the manuscript text for clarity and word-count reduction, and to help generate selected minor components of figures. All artificial intelligence generated content was reviewed, edited, and verified by the authors, who take full responsibility for the final manuscript and figures. Financial support and sponsorship There were no sources of funding for this article. The authors have no financial disclosures to report. Conflicts of interest Both authors partner with the Linda Crnic Institute for Down Syndrome at the University of Colorado on an investigator-initiated clinical trial. REFERENCES AND RECOMMENDED READING Papers of particular interest, published within the annual period of review, have been highlighted as: ▪ of special interest ▪ of special interest ▪▪ of outstanding interest ▪▪ of outstanding interest REFERENCES